bremzalerbart

**Bremzalerbart** is a human IgG4 monoclonal antibody that specifically binds to Bet v 1, the major allergenic protein from birch pollen (Betula species). It is designed to block Bet v 1-mediated allergic reactions, thereby reducing symptoms of birch pollen-induced allergic diseases such as allergic rhinitis and conjunctivitis. Bremzalerbart is one component of the clinical mixture REGN5713-5714-5715 and is being developed primarily for immune-mediated/inflammatory disorders such as seasonal allergic rhinitis and conjunctivitis. Its mechanism of action is direct inhibition of Bet v 1, preventing allergen-induced IgE cross-linking on mast cells and basophils, which in turn reduces histamine and other mediator release implicated in allergy symptoms[1][2][3][4].

Other names

immunoglobulin G4-kappa, anti-[Bet v 1 (Betula alleghaniensis pollen allergen 1)], Homo sapiens monoclonal antibody, gamma4 heavy chain Homo sapiens (1-443) [VH (Homo sapiens IGHV4-59*01 (88.5%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.7.10]Immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulfide with human monoclonal REGN5713 κ-chain, dimer